Celsion's silent approach

Celsion Corp. (NASDAQ: CLSN) has discovered that its TheraSilence delivery platform delivers RNA-based therapeutics efficiently to the lung - a feat beyond most RNA delivery systems, which on the whole reach only the liver. Now the company has disclosed its first therapeutic candidate that uses the platform, EGEN-002, and says it plans to pursue the compound for pulmonary arterial hypertension (PAH).

"Most delivery systems available for RNA are liver-specific," said EVP and CSO Khursheed Anwer. "The benefit of our system, which targets the pulmonary vasculature, is that we don't see liver activity or toxicity." ...